CDK12 is a potential biomarker for diagnosis, prognosis and immunomodulation in pan-cancer
Authors:
Open Access
- 19 March 2024
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-17
Abstract
Cell cycle-dependent protein kinase 12 (CDK12) plays a key role in a variety of carcinogenesis processes and represents a promising therapeutic target for cancer treatment. However, to date, there have been no systematic studies addressing its diagnostic, prognostic and immunological value across cancers. Here, we found that CDK12 was significantly upregulated in various types of cancers, and it expression increased with progression in ten cancer types, including breast cancer, cholangiocarcinoma and colon adenocarcinoma. Moreover, the ROC curves indicated that CDK12 showed diagnostic value in eight cancer types. High CDK12 expression was associated with poor prognosis in eight types of cancer, including low-grade glioma, mesothelioma, melanoma and pancreatic cancer. Furthermore, we conducted immunoassays to explore the exact mechanisms underlying CDK12-induced carcinogenesis, which revealed that increased expression of CDK12 allowed tumours to evade immune surveillance and upregulate immune checkpoint genes. Additionally, mutational studies have shown that amplification and missense mutations are the predominant mutational events affecting CDK12 across cancers. These findings establish CDK12 as a significant biological indicator of cancer diagnosis, prognosis, and immunotherapeutic targeting. Early surveillance and employment of CDK12 inhibitors, along with concomitant immunotherapy interventions, may enhance the clinical outcomes of cancer patients.Keywords
Funding Information
- National Natural Science Foundation of China (82000648, 82070735, 82241047, 82100615)
- Fundamental Research Funds for the Central Universities (2242023K40046)
- Outstanding Youth Cultivation Foundation of Southeast University (2021ZDYYYQPY07)
- Natural Science Foundation of Jiangsu Province (BK20200363)
This publication has 48 references indexed in Scilit:
- Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcomaEuropean Journal of Medicinal Chemistry, 2021
- Immune scores in colorectal cancer: Where are we?European Journal of Cancer, 2020
- Promoter DNA Hypermethylation and Paradoxical Gene ActivationTrends in Cancer, 2020
- Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast CancerCancer Cell, 2019
- Genomic Hallmarks and Structural Variation in Metastatic Prostate CancerCell, 2018
- The Immune Landscape of CancerImmunity, 2018
- EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing SarcomaCancer Cell, 2018
- CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast CancerCell Reports, 2016
- Comparison of Diagnostic Accuracy of Clinical Measures of Breast Cancer–Related Lymphedema: Area Under the CurveArchives of Physical Medicine and Rehabilitation, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011